AGP Executive Report
Last update: 9 hours agoASX Cannabis Pharma Watch: Neurotech International (ASX:NTI) is pushing a standardized, low-THC cannabinoid autism programme through conventional pharma steps, with a US clearance opening a parallel dosing study as recruitment ramps up. Clinical Trial Checkpoint: Avecho (ASX:AVE) got an independent monitoring board thumbs-up to continue its pivotal CBD insomnia trial at the planned size, restarting final-stage recruitment and supported by a global generics licence deal. Clinic Rollout: Emyria (ASX:EMD) keeps expanding its Empax clinic network across mainland states, with NSW training completed ahead of the next site opening and a reimbursement pathway via private insurance. Policy & Regulation: A Colombian medicinal cannabis policy effort is getting a detailed “evidence-to-decision” roadmap, aiming to close the science-to-rules gap for access, THC limits, and clinician training. Hemp THC Retail: Convenience stores are celebrating a federal delay on hemp THC restrictions, arguing for regulation over prohibition. Public Health Note: A Cleveland dispatcher faces child endangerment charges after her child tested positive for marijuana.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
